Current Report Filing (8-k)
March 10 2023 - 04:53PM
Edgar (US Regulatory)
0001673772false00016737722023-03-102023-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
|
Date of Report (Date of earliest event reported):
March 10, 2023
|
RAPT Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware
|
001-38997
|
47-3313701
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
561 Eccles Avenue
|
|
|
South San Francisco,
California
|
|
94080
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
Registrant’s Telephone Number, Including Area Code:
(650)
489-9000
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value per share
|
|
RAPT
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD Disclosure.
RAPT Therapeutics, Inc. (the “Company”) holds approximately $2
million of cash at Silicon Valley Bank. The remainder of the
Company’s cash and investments are held at a separate custodian
bank.
The information furnished under this Item 7.01 shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or subject to the liabilities of that section.
The information shall not be deemed incorporated by reference into
any other filing with the Securities and Exchange Commission made
by the Company, regardless of any general incorporation language in
such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
RAPT Therapeutics, Inc.
|
|
|
|
|
|
|
Date:
|
March 10, 2023
|
By:
|
/s/ Rodney Young
|
|
|
|
|
Rodney Young
Chief Financial Officer
|
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2023 to Jun 2023
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Jun 2022 to Jun 2023
